Search Results - "Robert, Lidia"

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma by ATEFI, Mohammad, AVRAMIS, Earl, COMIN-ANDUIX, Begonya, RIBAS, Antoni, LASSEN, Amanda, WONG, Deborah J. L, ROBERT, Lidia, FOULAD, David, CERNIGLIA, Michael, TITZ, Bjoern, CHODON, Thinle, GRAEBER, Thomas G

“…PD-L1 is the main ligand for the immune inhibitory receptor PD-1. This ligand is frequently expressed by melanoma cells. In this study, we investigated whether…”
Get full text

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma by Müller, Judith, Krijgsman, Oscar, Tsoi, Jennifer, Robert, Lidia, Hugo, Willy, Song, Chunying, Kong, Xiangju, Possik, Patricia A., Cornelissen-Steijger, Paulien D. M., Foppen, Marnix H Geukes, Kemper, Kristel, Goding, Colin R., McDermott, Ultan, Blank, Christian, Haanen, John, Graeber, Thomas G., Ribas, Antoni, Lo, Roger S., Peeper, Daniel S.

“…Increased expression of the Microphthalmia-associated transcription factor (MITF) contributes to melanoma progression and resistance to BRAF pathway…”
Get full text

MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells by Ploper, Diego, Taelman, Vincent F., Robert, Lidia, Perez, Brian S., Titz, Björn, Chen, Hsiao-Wang, Graeber, Thomas G., von Euw, Erika, Ribas, Antoni, De Robertis, Edward M.

“…Significance MITF, a master regulator of melanocytes and a major melanoma oncogene amplified in 30-40% of melanomas, determines proliferative or invasive…”
Get full text

Immunotherapy Resistance by Inflammation-Induced Dedifferentiation by Mehta, Arnav, Kim, Yeon Joo, Robert, Lidia, Tsoi, Jennifer, Comin-Anduix, Begoña, Berent-Maoz, Beata, Cochran, Alistair J, Economou, James S, Tumeh, Paul C, Puig-Saus, Cristina, Ribas, Antoni

“…A promising arsenal of targeted and immunotherapy treatments for metastatic melanoma has emerged over the last decade. With these therapies, we now face new…”
Get more information

Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line by Su, Yapeng, Ko, Melissa E., Cheng, Hanjun, Zhu, Ronghui, Xue, Min, Wang, Jessica, Lee, Jihoon W., Frankiw, Luke, Xu, Alexander, Wong, Stephanie, Robert, Lidia, Takata, Kaitlyn, Yuan, Dan, Lu, Yue, Huang, Sui, Ribas, Antoni, Levine, Raphael, Nolan, Garry P., Wei, Wei, Plevritis, Sylvia K., Li, Guideng, Baltimore, David, Heath, James R.

“…The determination of individual cell trajectories through a high-dimensional cell-state space is an outstanding challenge for understanding biological changes…”
Get full text

Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance by Su, Yapeng, Bintz, Marcus, Yang, Yezi, Robert, Lidia, Ng, Alphonsus H C, Liu, Victoria, Ribas, Antoni, Heath, James R, Wei, Wei

“…Phenotypic plasticity is associated with non-genetic drug tolerance in several cancers. Such plasticity can arise from chromatin remodeling, transcriptomic…”
Get full text

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma by Wong, Deborah JL, Robert, Lidia, Atefi, Mohammad S, Lassen, Amanda, Avarappatt, Geetha, Cerniglia, Michael, Avramis, Earl, Tsoi, Jennifer, Foulad, David, Graeber, Thomas G, Comin-Anduix, Begonya, Samatar, Ahmed, Lo, Roger S, Ribas, Antoni

“…Background In melanoma, dysregulation of the MAPK pathway, usually via BRAF.sup.V600 or NRAS.sup.Q61 somatic mutations, leads to constitutive ERK signaling…”
Get full text

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma by Lassen, Amanda, Atefi, Mohammad, Robert, Lidia, Wong, Deborah Jl, Cerniglia, Michael, Comin-Anduix, Begonya, Ribas, Antoni

“…The clinical use of BRAF inhibitors for treatment of metastatic melanoma is limited by the development of drug resistance. In this study we investigated…”
Get full text

Risk-Adapted Treatment in Clinical Stage I Testicular Seminoma: The Third Spanish Germ Cell Cancer Group Study by APARICIO, Jorge, MAROTO, Pablo, TERRASSA, Josefa, MEANA, Andrés, DEL PRADO, Purificación Martinez, SASTRE, Javier, SATRUSTEGUI, Juan J, GIRONES, Regina, ROBERT, Lidia, GERMA, José R, DEL MURO, Xavier García, GUMA, Josep, SANCHEZ-MUNOZ, Alfonso, MARGELI, Mireia, DOMENECH, Montserrat, BASTUS, Roma, FERNANDEZ, Antonio, LOPEZ-BREA, Marta

“…To confirm the efficacy of a risk-adapted treatment approach for patients with clinical stage I seminoma. The aim was to reduce both the risk of relapse and…”
Get full text

Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy by MOK, Stephen, KOYA, Richard C, TSUI, Christopher, JINGYING XU, ROBERT, Lidia, WU, Lily, GRAEBER, Thomas G, WEST, Brian L, BOLLAG, Gideon, RIBAS, Antoni

“…Colony stimulating factor 1 (CSF-1) recruits tumor-infiltrating myeloid cells (TIM) that suppress tumor immunity, including M2 macrophages and myeloid-derived…”
Get full text

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors by Su, Fei, Viros, Amaya, Milagre, Carla, Trunzer, Kerstin, Bollag, Gideon, Spleiss, Olivia, Reis-Filho, Jorge S, Kong, Xiangju, Koya, Richard C, Flaherty, Keith T, Chapman, Paul B, Kim, Min Jung, Hayward, Robert, Martin, Matthew, Yang, Hong, Wang, Qiongqing, Hilton, Holly, Hang, Julie S, Noe, Johannes, Lambros, Maryou, Geyer, Felipe, Dhomen, Nathalie, Niculescu-Duvaz, Dan, Niculescu-Duvaz, Ion, Zambon, Alfonso, Preece, Natasha, Robert, Lídia, Otte, Nicholas J, Mok, Stephen, Kee, Damien, Ma, Yan, Zhang, Chao, Habets, Gaston, Burton, Elizabeth A, Wong, Bernice, Nguyen, Hoa, Kockx, Mark, Andries, Luc, Lestini, Brian, Nolop, Keith B, Lee, Richard J, Joe, Andrew K, Troy, James L, Gonzalez, Rene, Hutson, Thomas E, Puzanov, Igor, Chmielowski, Bartosz, Springer, Caroline J, McArthur, Grant A, Sosman, Jeffrey A, Lo, Roger S, Ribas, Antoni, Marais, Richard

“…Patients with melanoma who are treated with a BRAF inhibitor have a high incidence of keratoacanthomas. Most of the tumors have oncogenic mutations in HRAS…”
Get full text

Combining targeted therapy with immunotherapy. Can 1 + 1 equal more than 2? by Robert, Lidia, Ribas, Antoni, Hu-Lieskovan, Siwen

“…Graphical abstract How can targeted therapy synergize immunotherapy?…”
Get full text

Combining Targeted Therapy With Immunotherapy in BRAF-Mutant Melanoma: Promise and Challenges by HU-LIESKOVAN, Siwen, ROBERT, Lidia, MORENO, Blanca Homet, RIBAS, Antoni

“…Recent breakthroughs in the treatment of advanced melanoma are based on scientific advances in understanding oncogenic signaling and the immunobiology of this…”
Get full text

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress by Tsoi, Jennifer, Robert, Lidia, Paraiso, Kim, Galvan, Carlos, Sheu, Katherine M., Lay, Johnson, Wong, Deborah J.L., Atefi, Mohammad, Shirazi, Roksana, Wang, Xiaoyan, Braas, Daniel, Grasso, Catherine S., Palaskas, Nicolaos, Ribas, Antoni, Graeber, Thomas G.

“…Malignant transformation can result in melanoma cells that resemble different stages of their embryonic development. Our gene expression analysis of human…”
Get full text

PD-1 blockade induces responses by inhibiting adaptive immune resistance by Tumeh, Paul C., Harview, Christina L., Yearley, Jennifer H., Shintaku, I. Peter, Taylor, Emma J. M., Robert, Lidia, Chmielowski, Bartosz, Spasic, Marko, Henry, Gina, Ciobanu, Voicu, West, Alisha N., Carmona, Manuel, Kivork, Christine, Seja, Elizabeth, Cherry, Grace, Gutierrez, Antonio J., Grogan, Tristan R., Mateus, Christine, Tomasic, Gorana, Glaspy, John A., Emerson, Ryan O., Robins, Harlan, Pierce, Robert H., Elashoff, David A., Robert, Caroline, Ribas, Antoni

“…The dynamics of T-cell responses are investigated in tumour tissue from patients with advanced melanoma who were treated with a PD-1-blocking monoclonal…”
Get full text

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma by Hu-Lieskovan, Siwen, Mok, Stephen, Homet Moreno, Blanca, Tsoi, Jennifer, Robert, Lidia, Goedert, Lucas, Pinheiro, Elaine M, Koya, Richard C, Graeber, Thomas G, Comin-Anduix, Begoña, Ribas, Antoni

“…Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability…”
Get more information

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance by Su, Yapeng, Wei, Wei, Robert, Lidia, Xue, Min, Tsoi, Jennifer, Garcia-Diaz, Angel, Moreno, Blanca Homet, Kim, Jungwoo, Ng, Rachel H., Lee, Jihoon W., Koya, Richard C., Comin-Anduix, Begonya, Graeber, Thomas G., Ribas, Antoni, Heath, James R.

“…Continuous BRAF inhibition of BRAF mutant melanomas triggers a series of cell state changes that lead to therapy resistance and escape from immune control…”
Get full text

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire by ROBERT, Lidia, TSOI, Jennifer, KOYA, Richard C, GRAEBER, Thomas G, ROBINS, Harlan, RIBAS, Antoni, XIAOYAN WANG, EMERSON, Ryan, HOMET, Blanca, CHODON, Thinle, MOK, Stephen, RONG RONG HUANG, COCHRAN, Alistair J, COMIN-ANDUIX, Begoña

“…To evaluate the immunomodulatory effects of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) blockade with tremelimumab in peripheral blood mononuclear…”
Get full text

Anti–PD-1 Therapy in Melanoma by Homet Moreno, Blanca, Parisi, Giulia, Robert, Lidia, Ribas, Antoni

“…Immune-regulatory mechanisms are used by cancer to hide from the immune system. Advances and in-depth understanding of the biology of melanoma and its…”
Get full text

Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC) by Schmid, Peter, Savas, Peter, Espinosa, Enrique, Boni, Valentina, Italiano, Antoine, White, Shane, Cheng, Karen, Lam, Lisa, Robert, Lidia, Laliman, Victor, Shah, Kalpit, Sablin, Marie-Paule

“…Abstract Background: The combination of immune checkpoint modulators with chemotherapy improves efficacy compared with chemotherapy alone in PD-L1+ advanced…”
Get full text